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Background/aim: Warfarin is a common anticoagulant with large interindividual differences and a narrow therapeutic range. The
polymorphisms of gamma-glutamyl carboxylase (GGCX) are important genetic factors for warfarin dose requirements.
Materials and methods: Polymerase chain reaction and direct sequencing methods were used to detect the GGCX rs699664 genotype
in 215 atrial fibrillation (AF) patients with warfarin administration. The effects on warfarin dose by different genotypes were analyzed.
A warfarin dosing algorithm was developed based on age, height, CYP2C9, VKORC1, and GGCX genotype.
Results: In 215 AF patients, there were 104 cases of wild-type GG genotype (48.4%), 92 cases of GA genotype (42.8%), and 19 cases of
AA genotype (8.8%). Patients with the GGCX rs699664 A allele (GA or AA genotypes) needed higher warfarin doses than those with
the GG genotype (P < 0.05). A warfarin dosing algorithm showed that age, height, CYP2C9, VKORC1, and GGCX genotype were the
best variables for estimating warfarin dose (R2 = 41.2%). Another independent cohort of 60 AF patients showed a significant linear
correlation between predicted warfarin maintenance dose and actual dose (R = 0.660, P < 0.01).
Conclusion: AF patients with the GA and AA genotypes in GGCX rs699664 required significantly higher warfarin doses. GGCX
rs699664 is a potential predictor for the warfarin dose of AF patients.
Key words: Atrial fibrillation, gamma-glutamyl carboxylase, warfarin, genetic polymorphisms

1. Introduction
Atrial fibrillation (AF) is the most common clinical cardiac
arrhythmia with high morbidity and mortality (1). The
incidence of AF is 1%–2% in the general population and
it is increased with age, heart failure, and hypertension (2–
4). AF patients have increased risk of complications, such
as strokes and systemic thromboembolism (5), which can
be reduced by anticoagulant therapy such as warfarin (6).
Warfarin is the most commonly used oral
anticoagulant drug and it has long been applied in the
prevention of various thromboembolic disorders, such
as prosthetic heart valves, deep venous thrombosis,
pulmonary embolism, and recurrent stroke (7). Due to
interindividual differences in drug responses, warfarin has
a narrow therapeutic range and inadequate or excessive
warfarin may result in thromboembolism or bleeding
(8). Therefore, it is essential to monitor and control the
warfarin dose within this therapeutic window in clinical
application.
Because of the interindividual variability in response to
warfarin, it is difficult to make accurate dose predictions.
* Correspondence: liyssh@163.com

Warfarin dose requirements can be influenced be
many factors, such as age, body size, environment,
interacting medications, and genetic polymorphisms,
thereby contributing to the interindividual variability
of warfarin dose response (9–11). Among these, genetic
polymorphisms, and especially single nucleotide
polymorphisms (SNPs), can affect the stable warfarin
dose, and these polymorphisms modulate warfarin’s
pharmacodynamics and pharmacokinetics, including
variants in genes coding for cytochrome P450 2C9
(CYP2C9) and vitamin K epoxide reductase complex
1 (VKORC1) (12,13). Therefore, to reduce the risk of
overanticoagulation and bleeding complications, many
warfarin dosing algorithms have been developed to predict
warfarin dose (14,15). A clinical trial confirmed that
using the warfarin dose predicted by pharmacogenetics is
superior to the standard warfarin dose in establishing and
maintaining anticoagulation therapy, thereby reducing the
risk of adverse events (16).
Gamma-glutamyl carboxylase (GGCX) is an enzyme
that affects the metabolism of warfarin by catalyzing the

1239

JIANG et al. / Turk J Med Sci
biosynthesis of vitamin K-dependent clotting factors.
Warfarin exerts its anticoagulant effects by inhibiting
the regeneration of a reduced form of vitamin K, which
is essential for γ-carboxylation and activation of vitamin
K-dependent clotting factors (factors II, VII, IX, and X)
(17). It has been reported that genetic polymorphisms in
the GGCX gene can influence the variability of warfarin
dose response in the general population (18–20). In this
study, we aimed to investigate the contribution of GGCX
polymorphism rs699664 to warfarin dose requirement in
AF patients and to develop and evaluate a warfarin dosing
algorithm based on the GGCX genotype in AF patients.
2. Materials and methods
2.1. Study population
The study population consisted of 275 AF patients from
January 2014 to March 2016 at Shanghai Seventh People’s
Hospital. All the patients were Han Chinese individuals
who lived in Shanghai in eastern China. The inclusion
criteria for study subjects were as follows: 1) patients were
≥18 years old and had received a stable maintenance dose
of warfarin therapy for at least 3 months; 2) a balanced
diet was followed in each case and smoking and drinking
were forbidden; 3) patients did not take any medications
that might interfere with the pharmacokinetics or
pharmacodynamics of warfarin; 4) patients had no
hepatic or renal impairments according to laboratory
tests; 5) during the warfarin therapy, patients showed
no hemorrhage or thrombosis complications. Clinical
data were collected from each AF patients on age, sex,
height, body weight, left atrial size, ejection fraction, and
maintenance dose of warfarin. On arrival at the hospital,
plasma and blood samples were obtained. All 275 AF
patients were divided into a discovery cohort (215 cases)
and a replication cohort (60 cases). The discovery cohort
was used to investigate the effect of GGCX genotype
on warfarin dose and produce the dose algorithm for
estimating the warfarin dose. The replication cohort was
used to evaluate the feasibility of the warfarin dosing
algorithm in AF patients. All patients provided written

informed consent for study participation. This study was
approved by the Ethics Committee of Shanghai Seventh
People’s Hospital. All study procedures were conducted in
accordance with the Declaration of Helsinki.
2.2. GGCX genotyping
Peripheral venous blood samples were obtained from AF
patients and genomic DNA was extracted from leukocytes
with a DNA extraction kit (QIAGEN, Crawley, UK).
The polymorphisms of CYP2C9 (rs1057910), VKORC1
(rs9923231), and GGCX (rs699664) were determined by
polymerase chain reaction (PCR) and direct sequencing.
PCR primers were designed using Primer3 software
(http://bioinfo.ut.ee/primer3-0.4.0/) and were synthesized
by Shanghai Sangon Biological Engineering Co., Ltd.
(Table 1). PCR amplification was performed in a C1000
Touch Thermal Cycler PCR instrument (Bio-Rad,
Hercules, CA, USA) in a final volume of 20 µL, containing
0.25 µM primer, 0.1 mM deoxynucleoside triphosphate
(dNTP), 0.625 U Taq polymerase (Molzyme, Bremen,
Germany), and 0.5 µg genomic DNA. Thermocycling
consisted of initial denaturation at 95 °C for 10 min,
followed by 40 cycles of denaturation at 95 °C for 40 s,
annealing at 56 °C for 30 s, and extension at 72 °C for 30
s, with a final extension of 72 °C for 10 min. The amplified
PCR products were purified and sequenced by Shanghai
Sangon Biological Engineering Co., Ltd.
2.3. Statistical analysis
Continuous variables were expressed as medians and
interquartile ranges. Categorical variables were expressed
as frequencies and percentages. The statistical analysis
was performed with SPSS 19.0 (IBM Corp., Armonk,
NY, USA). The Wilcoxon–Mann–Whitney test was used
to compare continuous data and the chi-square test or
Fisher’s exact test was used to compare categorical data.
Multivariate linear regression was performed to develop
a novel warfarin dosing algorithm. Spearman’s rank
correlation test was performed to analyze the correlation
between actual warfarin dose and warfarin dose predicted
by the algorithm. P < 0.05 was considered statistically
significant.

Table 1. PCR primers for CYP2C9, VKORC1, and GGCX.
Variant
CYP2C9 rs1057910
VKORC1 rs9923231
GGCX rs699664
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Primers (5’ to 3’)
Forward: CACGAGGTCCAGAGATACA
Reverse: GGAATGAGATAGTTTCTGAATTTAAT
GCCAGCAGGAGAGGGAAATA
AGTTTGGACTACAGGTGCCT
AGTGGCCTCGGAAGCTGGT
ACACAGGAAACACTGGGCTGAG
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3. Results
3.1. Patient characteristics
The discovery cohort consisted of 215 AF patients with
stable control of anticoagulation and was used to investigate
the association between GGCX genotype and warfarin
dose, and the replication cohort consisted of 60 patients
to confirm the efficacy of the warfarin dosing algorithm.
There were no statistically significant differences between
the discovery cohort and replication cohort in age, sex,
height, weight, left atrial size, ejection fraction, INR, or
warfarin dose requirements.
3.2. GGCX genotyping
All 215 samples were genotyped for GGCX (rs699664),
as this polymorphism was previously reported to affect
warfarin dose requirements. There were 104 (48.4%)
subjects with the homozygous GG genotype, 92 (42.8%)
subjects with the heterozygous GA genotype, and 19
(8.8%) subjects with the homozygous AA genotype (Table

2). The observed genotype frequency of GGCX (rs699664)
showed no deviation from Hardy–Weinberg equilibrium.
3.3. Associations of warfarin dose with GGCX genotype
The median warfarin daily dose requirement was 3.0 ±
0.79 mg in heterozygous GGCX GA patients, which was
significantly higher than that in homozygous wild-type
GGCX GG patients (2.7 ± 0.77 mg, P < 0.05). Furthermore,
the median warfarin daily dose requirement was 3.7 ± 0.87
mg in patients with the GGCX AA genotype, which was
significantly higher than that in patients with the GG or
GA genotype (P < 0.05) (Figure 1). We also divided the
discovery cohort into a low warfarin group and a high
warfarin group according to the median warfarin dose (2.9
mg/day). The high warfarin group showed a significantly
higher frequency of GA and AA genotypes as well as
younger age and taller height compared with the low
warfarin group (Table 2).

Table 2. Clinical demographics of the discovery cohort and replication cohort.
Characteristics

Discovery cohort
(n = 215)

Discovery cohort (<2.9 mg)
(n = 99)

Discovery cohort (≥2.9 mg)
(n = 116)

Replication cohort
(n = 60)

Age (years) †

56 (47–66)

59 (52–69)

52 (43–62) *

54 (45–63)

Sex #

136 (63.3%)

60 (60.6%)

76 (65.5%)

35 (58.3%)

Height (cm) †

170 (161–175)

170 (159–173)

172 (162–176) *

168 (158–175)

Weight (kg) †

66 (54–72)

66 (55–71)

67 (54–73)

64 (57–72)

Left atrial size (mm) †

46 (43–51)

47 (41–52)

46 (43–51)

48 (42–57)

Ejection fraction (%) †

49.3 (44.8–57.4)

51.4 (44.8–61.1)

49.3 (44.9–57.0)

51.1 (47.0–57.4)

INR †

2.8 (2.2–3.2)

2.6 (1.8–3.2)

2.8 (2.6–3.2)

2.7 (2.2–3.0)

Warfarin dose (mg) †

2.9 (2.5–3.3)

2.5 (2.3–2.6)

3.3 (3.1–3.7)

2.9 (2.4–3.2)

*1*1

198 (92.1%)

85 (85.9%)

113 (97.4%)*

54 (90.0%)

*1*3

17 (7.9%)

14 (14.1%)

3 (2.6%)

6 (10.0%)

AA

158 (73.5%)

87 (87.9%)

71 (61.2%)*

49 (81.7%)

AG

52 (24.2%)

11 (11.1%)

41 (35.3%)

10 (16.7%)

GG

5 (2.3%)

1 (1.0%)

4 (3.4%)

1 (1.7%)

GG

104 (48.4%)

59 (59.6%)

45 (38.8%)*

28 (46.7%)

GA

92 (42.8%)

37 (37.4%)

55 (47.4%)

26 (43.3%)

AA

19 (8.8%)

3 (3.0%)

16 (13.8%)

6 (10.0%)

CYP2C9 #

VKORC1 #

GGCX #

# Categorical variables are expressed as frequency (%) and analyzed by chi-square test; † continuous variables are expressed as medians
(25th to 75th percentiles) and analyzed by Mann–Whitney U test.
*Compared with the discovery cohort group, the difference is significant (P < 0.05).
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Figure 1. Warfarin dose in different GGCX genotypes. In box plots, bold black line indicates the
median per group, the box represents interquartile ranges (25%–75%) of the values, and horizontal
lines indicate minimum and maximum values; open circles indicate outlier values. The Wilcoxon–
Mann–Whitney test was performed. *P < 0.05, **P < 0.01, ***P < 0.001.

3.4. Warfarin dosing algorithm
We performed multivariate linear regression analysis to
detect variables that influence the warfarin dose. Results
showed that age, height, CYP2C9, VKORC1, and GGCX
genotype could develop models for estimating the warfarin
dose (adjusted R2 = 0.412) (Table 3). To verify the accuracy
of this algorithm, we used Spearman’s rank correlation test
in the replication cohort of 60 AF patients and showed a

significant correlation between the calculated warfarin
dose using the warfarin dosing algorithm and actual dose
(R = 0.660; P < 0.001) (Figure 2).
4. Discussion
In this study, we investigated the genotype of GGCX
rs699664 in a discovery cohort of 215 AF patients, and
the results showed that there were 104 (48.4%) cases of

Table 3. Regression equation for modeling warfarin daily dose requirements based on age,
height, and genotypes.
X variables

Standardized coefficient

Adjusted R2

P

Age

–0.008

0.029

0.002

Height

0.009

0.011

0.029

CYP2C9

–0.620

0.070

<0.001

VKORC1

0.439

0.172

<0.001

GGCX

0.257

0.130

<0.001

Regression equation: dose = 1.726 – 0.008 (age) + 0.009 (height) – 0.620 (CYP2C9) + 0.439
(VKORC1) + 0.257 (GGCX). Adjusted R2 = 0.412.
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Figure 2. Correlation of calculated warfarin dose using warfarin dosing algorithm and actual dose
in the replication cohort of AF patients. Each patient within the replication cohort is represented
by a circle.

wild-type homozygous GG genotype, 92 (42.8%) cases
of heterozygous GA genotype, and 19 (8.8%) cases of
homozygous AA genotype. Patients carrying the GGCX
rs699664 A allele (GA or AA genotype) had significantly
higher warfarin dose requirements than those with the GG
genotype (P < 0.05). A multivariate linear regression model
was used to develop a warfarin dosing algorithm and
showed that age, height, CYP2C9, VKORC1, and GGCX
genotype were the best variables for estimating warfarin
dose (R2 = 41.2%). Another independent replication cohort
of 60 AF patients showed a significant linear correlation
between actual warfarin dose and warfarin maintenance
dose as predicted by the warfarin dosing algorithm (R =
0.660, P<0.01).
GGCX is a vitamin K-dependent carboxylase and
could promote the biosynthesis of vitamin K-dependent
clotting factors (21,22). GGCX resides in the endoplasmic
reticulum membrane and oxidizes reduced vitamin
K to vitamin K-2,3-epoxide though carboxylation of
the gamma carbon on glutamic acids, thus producing
functional vitamin K-dependent clotting factors II, VII,
IX, and X (23,24). GGCX-knockout mice die from massive
hemorrhaging at birth (25). Patients with defective GGCX
have elevated INR values (26). The GGCX gene is located on
human chromosome 2p12 and consists of 15 exons (27,28).

Over the past decades, extensive studies have investigated
the association between GGCX polymorphisms and
warfarin maintenance dose requirements (17–20).
The common GGCX polymorphisms include GGCX
rs11676382, rs12714145, rs10654848, and rs699664.
GGCX rs11676382 (C>G) SNP is located in intron 14
and correlated with lower warfarin dose requirements in
Caucasians (20,29). The GGCX rs12714145 (3261G>A)
SNP is located in intron 2 and subjects with the AA
genotype have significantly higher warfarin dose
requirements compared with the GG genotype in Chinese
patients (30). The GGCX rs10654848 microsatellite
(CAA repeats) is located in intron 6 and correlated with
higher warfarin dose requirements in Caucasians and
African Americans (31,32). GGCX rs699664 is defined
by a G-to-A nucleotide substitution (8016G>A), thus
leading to a nonsynonymous substitution and a change
from arginine to glutamine at amino acid position 325
in exon 8. It is correlated with higher warfarin dose
requirements in Japanese and Chinese patients (33,34).
However, rs699664 was not associated with warfarin dose
in Caucasians or African Americans (31,32), indicating
the ethnic differences in warfarin metabolism. In this
study, we found that the GGCX rs699664 polymorphism
was associated with higher warfarin dose requirements in
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Chinese AF patients, suggesting that it may be a potential
predictor for warfarin maintenance dose.
We found a significant association of warfarin dose
with CYP2C9 and VKORC1 genotype, as evidenced by
differences in the frequencies of CYP2C9 rs1057910
and VKORC1 rs9923231 between the low warfarin dose
group and high warfarin dose group. CYP2C9 is one
isoform of the cytochrome P450 complex and metabolizes
approximately 15% of the clinically used drugs (35).
Among the various variants of CYP2C9 being identified,
CYP2C9*3 is the most common allele (rs1057910).
Compared with the wild-type CYP2C9*1, CYP2C9*3 is
defined by an A-to-C nucleotide substitution (1075 A>C),
thus leading to a nonsynonymous substitution and a change
from leucine to isoleucine at amino acid position 359 in
exon 7. The CYP2C9*3 allele could reduce the activity
of CYP2C9 and decrease the metabolism and clearance
capability of warfarin, thus enhancing the sensitivity to
warfarin and reducing warfarin dose requirements. Our
previous report demonstrated that AF patients with the
CYP2C9 *1*3 genotype had lower stable warfarin daily
doses compared with patients with wild-type CYP2C9
*1*1 (36). VKORC1 is responsible for the biosynthesis
of vitamin K-dependent coagulation factors (factors
II, VII, IX, and X) through transformation of epoxide
(vitamin K-2,3-epoxide) to a reduced form of vitamin K
and gamma-carboxylation of the vitamin K-dependent
coagulation factors (37). Warfarin inhibits VKORC1catalyzed gamma-carboxylation of coagulation factors,
thus preventing the regeneration of the reduced form of
vitamin K (38). Mutations in the VKORC1 gene can lead
to warfarin resistance, which might enhance warfarin dose
requirements (39,40). VKORC1 rs9923231 (-1639 G>A) is
the most common SNP of the VKORC1 gene. Compared
with Caucasian populations, Chinese populations have
higher A allele rates and the AA genotype frequency is
above 83% (41). In this study, the VKORC1 rs9923231 AA
genotype frequency was significantly lower in the high
warfarin group compared with the low warfarin group.
Our results are in accordance with another report finding
that a higher warfarin dose is needed in subjects with the
GG genotype than subjects with the AG or AA genotype
(42).
In this study, we found that there was a significant
association between GGCX rs699664 polymorphism and
sensitivity to warfarin in Chinese AF patients, suggesting

that it may be a useful predictor of warfarin maintenance
dose. Therefore, we developed a dosing algorithm by
multivariate linear regression analysis and showed that
variables such as age, height, CYP2C9, VKORC1, and
GGCX genotype can be used to estimate the warfarin
maintenance dose. To evaluate the accuracy of this dosing
algorithm, we applied Spearman’s rank correlation test
to an independent replication cohort of 60 AF patients
and showed a significant correlation between the actual
warfarin dose and the warfarin dose predicted by the
dosing algorithm (R = 0.660; P < 0.001). This indicates that
GGCX rs699664 participates in warfarin dose variation
and it could be added to the warfarin dosing algorithm
following CYP2C9 and VKORC1.
Though we found that the CYP2C9 rs1057910,
VKORC1 rs9923231, and GGCX rs699664 genotypes were
correlated to warfarin dose requirements, there are some
limitations in our study. The sample size is small and all
of the AF patients included in the study were limited to
Han Chinese individuals of East China. Therefore, further
studies with a larger sample size and different populations
are required to confirm the results. Furthermore, the
mechanism by which GGCX rs699664 influences the
warfarin dose requirements remains unknown. Based on
higher warfarin dose requirements in subjects with the AA
genotype, it seems plausible that the A allele may enhance
GGCX enzyme activity and promote carboxylation of
clotting factors, thereby leading to warfarin resistance
and presumably enhancing warfarin dose requirements.
However, the detailed mechanism remains to be
investigated.
In conclusion, this study provides evidence that patients
with the GGCX rs699664 AA genotype required higher
warfarin doses in the Chinese AF patient population. The
GGCX rs699664 genotype might help clinicians to guide
warfarin dosage by a new warfarin dosing algorithm
in AF patients. However, further studies are needed to
confirm this study with a larger sample size and different
populations.
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